Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Debiopharm International SA
With
Caris Life Sciences
Optimal Research (Just In Time sites)
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Cytologically or histologically confirmed advanced solid tumor
Radiographic progression on prior systemic therapy; prior localized therapy (i.e., radiation, ablation, embolization) is allowed provided radiographic progression out-of-field or in the treatment, field is shown
Locally-advanced (unresectable) or metastatic disease harboring an FGFR1-3 gene fusion/rearrangement potentially leading to a functional FGFR aberrant protein, identified through local and/or central molecular assay
You may not be if
History of hypersensitivity to any of the excipients in the Debio 1347 formulation
History and/or current evidence of ectopic mineralization/calcification, including but not limited to soft tissue, kidneys, intestine, myocardia, or lung, excepting calcified lymph nodes, lung nodules and asymptomatic vascular or cartilage/tendon calcifications
Administration of any investigational agent within 2 weeks prior to initial dosing with Debio 1347 (3 weeks for immune checkpoint inhibitors)
Clareo Health | Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)
